Latest Breaking News On - Biocryst pharmaceuticals price performance - Page 1 : comparemela.com

Oracle Investment Management Inc. reduced its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 3.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 535,558 shares of the biotechnology company’s stock after selling 19,964 shares during the period. […]

Alang levinStevenk galsonExchange commissionSecurities exchange commissionNews ratings for biocryst pharmaceuticals dailyQuarter for biocryst pharmaceuticalsDeerfield management companylp seriesVanguard group incNeedham companyOracle investment management incRafferty asset managementNorges bankBiocryst pharmaceuticalsBiocryst pharmaceuticals price performanceBiocryst pharmaceuticals incOracle investment management